vs

Side-by-side financial comparison of WORLD ACCEPTANCE CORP (WRLD) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

WORLD ACCEPTANCE CORP is the larger business by last-quarter revenue ($141.3M vs $127.1M, roughly 1.1× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs 1.9%). WORLD ACCEPTANCE CORP produced more free cash flow last quarter ($57.2M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs -5.8%).

Credit Acceptance Corporation is an auto finance company providing automobile loans and other related financial products. The company operates its financial program through a national network of dealer-partners, the automobile dealers participating in the programs. The company operates two programs: the "Portfolio Program" and the "Purchase Program". Through these programs, the company can advance money to automobile dealers in exchange for the right to service the underlying consumer loans a...

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

WRLD vs ZLAB — Head-to-Head

Bigger by revenue
WRLD
WRLD
1.1× larger
WRLD
$141.3M
$127.1M
ZLAB
Growing faster (revenue YoY)
ZLAB
ZLAB
+15.2% gap
ZLAB
17.1%
1.9%
WRLD
More free cash flow
WRLD
WRLD
$83.9M more FCF
WRLD
$57.2M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
-5.8%
WRLD

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
WRLD
WRLD
ZLAB
ZLAB
Revenue
$141.3M
$127.1M
Net Profit
$-911.3K
Gross Margin
51.0%
Operating Margin
-0.7%
-54.6%
Net Margin
-0.6%
Revenue YoY
1.9%
17.1%
Net Profit YoY
-106.8%
EPS (diluted)
$-0.19
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
WRLD
WRLD
ZLAB
ZLAB
Q4 25
$141.3M
$127.1M
Q3 25
$134.5M
$115.4M
Q2 25
$132.5M
$109.1M
Q1 25
$165.3M
$105.7M
Q4 24
$138.6M
$108.5M
Q3 24
$131.4M
$101.8M
Q2 24
$129.5M
$100.1M
Q1 24
$159.3M
$87.1M
Net Profit
WRLD
WRLD
ZLAB
ZLAB
Q4 25
$-911.3K
Q3 25
$-1.9M
$-36.0M
Q2 25
$1.3M
$-40.7M
Q1 25
$44.3M
$-48.4M
Q4 24
$13.4M
Q3 24
$22.1M
$-41.7M
Q2 24
$9.9M
$-80.3M
Q1 24
$35.1M
$-53.5M
Gross Margin
WRLD
WRLD
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
WRLD
WRLD
ZLAB
ZLAB
Q4 25
-0.7%
-54.6%
Q3 25
-1.3%
-42.3%
Q2 25
1.5%
-50.3%
Q1 25
33.3%
-53.3%
Q4 24
11.6%
-62.6%
Q3 24
21.3%
-66.6%
Q2 24
10.0%
-76.0%
Q1 24
29.3%
-80.7%
Net Margin
WRLD
WRLD
ZLAB
ZLAB
Q4 25
-0.6%
Q3 25
-1.4%
-31.2%
Q2 25
1.0%
-37.3%
Q1 25
26.8%
-45.8%
Q4 24
9.7%
Q3 24
16.8%
-40.9%
Q2 24
7.7%
-80.2%
Q1 24
22.0%
-61.4%
EPS (diluted)
WRLD
WRLD
ZLAB
ZLAB
Q4 25
$-0.19
$-0.05
Q3 25
$-0.38
$-0.03
Q2 25
$0.25
$-0.04
Q1 25
$8.07
$-0.04
Q4 24
$2.45
$-0.09
Q3 24
$3.99
$-0.04
Q2 24
$1.79
$-0.08
Q1 24
$6.02
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
WRLD
WRLD
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$10.0M
$689.6M
Total DebtLower is stronger
$677.2M
Stockholders' EquityBook value
$351.6M
$715.5M
Total Assets
$1.1B
$1.2B
Debt / EquityLower = less leverage
1.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
WRLD
WRLD
ZLAB
ZLAB
Q4 25
$10.0M
$689.6M
Q3 25
$14.9M
$717.2M
Q2 25
$8.1M
$732.2M
Q1 25
$4.7M
$757.3M
Q4 24
$10.3M
$779.7M
Q3 24
$9.7M
$616.1M
Q2 24
$11.1M
$630.0M
Q1 24
$5.2M
$650.8M
Total Debt
WRLD
WRLD
ZLAB
ZLAB
Q4 25
$677.2M
Q3 25
$584.6M
Q2 25
$472.5M
Q1 25
$447.9M
Q4 24
$561.2M
Q3 24
$506.6M
Q2 24
$494.7M
Q1 24
$498.4M
Stockholders' Equity
WRLD
WRLD
ZLAB
ZLAB
Q4 25
$351.6M
$715.5M
Q3 25
$365.6M
$759.9M
Q2 25
$427.9M
$791.7M
Q1 25
$439.5M
$810.8M
Q4 24
$428.2M
$840.9M
Q3 24
$417.5M
$667.7M
Q2 24
$422.6M
$704.2M
Q1 24
$424.4M
$762.2M
Total Assets
WRLD
WRLD
ZLAB
ZLAB
Q4 25
$1.1B
$1.2B
Q3 25
$1.1B
$1.2B
Q2 25
$1.0B
$1.2B
Q1 25
$1.0B
$1.2B
Q4 24
$1.1B
$1.2B
Q3 24
$1.0B
$985.3M
Q2 24
$1.0B
$987.4M
Q1 24
$1.1B
$988.4M
Debt / Equity
WRLD
WRLD
ZLAB
ZLAB
Q4 25
1.93×
Q3 25
1.60×
Q2 25
1.10×
Q1 25
1.02×
Q4 24
1.31×
Q3 24
1.21×
Q2 24
1.17×
Q1 24
1.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
WRLD
WRLD
ZLAB
ZLAB
Operating Cash FlowLast quarter
$58.0M
$-26.0M
Free Cash FlowOCF − Capex
$57.2M
$-26.7M
FCF MarginFCF / Revenue
40.5%
-21.0%
Capex IntensityCapex / Revenue
0.6%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$412.5M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
WRLD
WRLD
ZLAB
ZLAB
Q4 25
$58.0M
$-26.0M
Q3 25
$48.6M
$-32.0M
Q2 25
$58.2M
$-31.0M
Q1 25
$254.2M
$-61.7M
Q4 24
$61.1M
$-55.8M
Q3 24
$53.8M
$-26.8M
Q2 24
$48.4M
$-42.2M
Q1 24
$265.8M
$-90.1M
Free Cash Flow
WRLD
WRLD
ZLAB
ZLAB
Q4 25
$57.2M
$-26.7M
Q3 25
$47.7M
$-35.0M
Q2 25
$57.1M
$-33.9M
Q1 25
$250.5M
$-63.2M
Q4 24
$60.4M
$-58.4M
Q3 24
$52.7M
$-28.2M
Q2 24
$47.3M
$-42.9M
Q1 24
$259.9M
$-91.1M
FCF Margin
WRLD
WRLD
ZLAB
ZLAB
Q4 25
40.5%
-21.0%
Q3 25
35.5%
-30.4%
Q2 25
43.1%
-31.1%
Q1 25
151.6%
-59.9%
Q4 24
43.6%
-53.8%
Q3 24
40.1%
-27.7%
Q2 24
36.5%
-42.9%
Q1 24
163.2%
-104.5%
Capex Intensity
WRLD
WRLD
ZLAB
ZLAB
Q4 25
0.6%
0.5%
Q3 25
0.7%
2.6%
Q2 25
0.8%
2.6%
Q1 25
2.2%
1.5%
Q4 24
0.5%
2.4%
Q3 24
0.8%
1.3%
Q2 24
0.8%
0.7%
Q1 24
3.7%
1.1%
Cash Conversion
WRLD
WRLD
ZLAB
ZLAB
Q4 25
Q3 25
Q2 25
43.27×
Q1 25
5.74×
Q4 24
4.56×
Q3 24
2.43×
Q2 24
4.87×
Q1 24
7.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

WRLD
WRLD

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons